Top

Published in:

01-12-2020 | Coronavirus | COVID-19

Update on cerebrovascular manifestations of COVID-19

Authors: Reza Naeimi, Maryam Ghasemi–Kasman

Published in: Neurological Sciences | Issue 12/2020

Abstract

The novel member of coronaviruses family, severe acute respiratory coronavirus-2 (SARS-CoV-2), with high structural homology to SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS) has spread rapidly with about 20 million cases infection and over 700,000 deaths. SARS-CoV-2 has been emerged as a worldwide disaster due to non-specific few respiratory and gastrointestinal manifestations at the onset of disease as well as long incubation period. Surprisingly, not only respiratory failure but also the underlying coagulation disorder and neurovascular involvement worsen the clinical outcome of infected patients. In this review article, we describe the probable mechanisms of SARS-CoV-2 infection and stroke occurrence. We will also discuss the cerebrovascular events following SARS-CoV-2 infection, the recommended therapies, and future prospects to better manage these patients in coronavirus disease 2019 (COVID-19) outbreak.

Wang C, Horby PW, Hayden FG, Gao GF (2020) A novel coronavirus outbreak of global health concern. Lancet 395(10223):470–473CrossRef

Organization, W.H., WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. 2020

Jin H et al (2020) Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc. Neurol:svn-2020–sv000382

Dalan R, Bornstein SR, el-Armouche A, Rodionov RN, Markov A, Wielockx B, Beuschlein F, Boehm BO (2020) The ACE-2 in COVID-19: foe or friend? Horm Metab Res 52(5):257–263CrossRef

Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li D, Li J, Lian H, Niu S, Zhang L, Zhang J (2020) Characteristics of COVID-19 infection in Beijing. J Inf Secur 80:401–406

Cao X (2020) COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20(5):269–270CrossRef

Mao, L., et al., Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. 2020

Yavarpour-Bali H, Ghasemi-Kasman M (2020) Update on neurological manifestations of COVID-19. Life Sci 257:118063CrossRef

Montalvan V, Lee J, Bueso T, de Toledo J, Rivas K (2020) Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 194:105921CrossRef

10.

Mansoor, S.R. and Ghasemi-Kasman, M, Impact of disease-modifying drugs on severity of COVID-19 infection in multiple sclerosis patients. Journal of Medical Virology. n/a(n/a)

11.

Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD (2020) Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J. Neurointerv. Surg 12(7):648–653CrossRef

12.

Helms J et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med:1–10

13.

Aggarwal G, Lippi G, Michael Henry B (2020) Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke 15(4):385–389CrossRef

14.

Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 92(6):552–555CrossRef

15.

Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong ASY (2005) Multiple organ infection and the pathogenesis of SARS. J Exp Med 202(3):415–424CrossRef

16.

Qin, C., et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases, 2020

17.

Mehta P et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033CrossRef

18.

Giannis D, Ziogas IA, Gianni P (2020) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 127:104362CrossRef

19.

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Am. J. Hematol 135(23):2033–2040

20.

Jose, R.J. and A. Manuel, COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine, 2020

21.

Leslie-Mazwi T et al (2020) Preserving access: a review of stroke thrombectomy during the COVID-19 pandemic. Am J Neuroradiol 41:1136–1141CrossRef

22.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506CrossRef

23.

Machado, C. J.V. Gutierrez, Brainstem dysfunction in SARS-COV2 infection can be a potential cause of respiratory distress. 2020

24.

Markus HS, Brainin M (2020) COVID-19 and stroke—a global World Stroke Organization perspective. Int J Stroke 15(4):361–364CrossRef

25.

Zeng J-H et al (2020) First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection:1

26.

Juusela A, Nazir M, Gimovsky M (2020) Two cases of COVID-19 related cardiomyopathy in pregnancy. Am J Obstet Gynecol:100113

27.

Inciardi, R.M., et al., Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA cardiology, 2020

28.

Lippi G, Plebani M (2020) Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med 58(7):1131–1134CrossRef

29.

Oudit G et al (2009) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Investig 39(7):618–625CrossRef

30.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang S (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38CrossRef

31.

Harzallah, I., A. Debliquis, B. Drénou, Lupus anticoagulant is frequent in patients with Covid-19. Journal of thrombosis and haemostasis : JTH, 2020

32.

Beyrouti, R., et al., Characteristics of ischaemic stroke associated with COVID-19. Journal of Neurology, Neurosurgery & Psychiatry, 2020

33.

Avula, A., et al., COVID-19 presenting as stroke. Brain, behavior, and immunity, 2020

34.

Hughes C et al (2020) Cerebral venous sinus thrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med:7(5)

35.

González-Pinto, T., et al., Emergency room neurology in times of COVID-19: malignant ischemic stroke and SARS-COV2 infection. European journal of neurology, 2020

36.

Al Saiegh, F., et al., Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. Journal of Neurology, Neurosurgery & Psychiatry, 2020

37.

Viguier, A., et al., Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection. Journal of neuroradiology, 2020

38.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, de Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fifi JT (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60CrossRef

39.

Yeboah, K., et al., Interventional stroke management in a COVID-19 patient. Neurology: Clinical Practice, 2020

40.

Immovilli P et al (2020) Stroke in COVID-19 patients—a case series from Italy. Int J Stroke:1747493020938294

41.

Klok F et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res

42.

Belani P, Schefflein J, Kihira S, Rigney B, Delman BN, Mahmoudi K, Mocco J, Majidi S, Yeckley J, Aggarwal A, Lefton D, Doshi AH (2020) COVID-19 is an independent risk factor for acute ischemic stroke. Am J Neuroradiol 41:1361–1364CrossRef

43.

Siegler J et al (2020) Falling stroke rates during COVID-19 pandemic at a Comprehensive Stroke Center: Cover title: Falling stroke rates during COVID-19. J Stroke Cerebrovasc Dis:104953

44.

Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M, for the Sepsis Definitions Task Force (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 315(8):775–787CrossRef

45.

Lyons PG, Micek ST, Hampton N, Kollef MH (2018) Sepsis-associated coagulopathy severity predicts hospital mortality. Crit Care Med 46(5):736–742CrossRef

46.

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef

47.

Lippi G, Plebani M, Henry BM (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta

48.

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18(5):1023–1026CrossRef

49.

Baracchini C et al (2020) Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci:1–3

50.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099CrossRef

51.

Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, Tang C, Zhang N, Zhong N, Li S (2020) Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 7(5):e362–e363CrossRef

52.

Ciavarella A, Peyvandi F, Martinelli I (2020) Where do we stand with antithrombotic prophylaxis in patients with COVID-19? Thromb Res 191:29CrossRef

53.

Lee M, Chen C, Ovbiagele B (2020) Covert COVID-19 complications: continuing the use of evidence-based drugs to minimize potentially lethal indirect effects of the pandemic in stroke patients. J Neurol Sci 414:116883–116883CrossRef

54.

Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, Lewis A, Melmed K, Hochman K, Horwitz L, Galetta S, Berger J (2020) Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis 29:104984CrossRef

Title: Update on cerebrovascular manifestations of COVID-19
Authors: Reza Naeimi
Maryam Ghasemi–Kasman
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Coronavirus
Stroke
SARS-CoV-2
COVID-19
Published in: Neurological Sciences / Issue 12/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04837-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Update on cerebrovascular manifestations of COVID-19

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome

The role of microglia in the development of neurodegeneration

The role of peripheral monocytes and macrophages in ischemic stroke

West syndrome: a comprehensive review

Application of the p9NORM correction method to timed neuropsychological tests in Parkinson’s disease and multiple system atrophy

Understanding the links between hearing impairment and dementia: development and validation of the Social and Emotional Impact of Hearing Impairment (SEI-HI) questionnaire